| Name | Title | Contact Details |
|---|
National Dental Association is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A leading specialty formulator and contract manufacturer of enzyme and probiotic-based dietary supplements.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Barnabas Health provides treatment and services for more than two million patients each year: 198,000 inpatients and Same Day Surgery patients; 452,000 Emergency Department patients; and 1.5 million outpatients; and delivers more than 18,300 babies annually. Our 18,200 employees, 4,600 physicians and 445 residents and interns are united in our mission to deliver the highest quality of care in the best possible environment. Among our nationally renowned services are: New Jersey’s only certified burn treatment facility, world-class cardiac surgery services for adults; the oldest, most experienced heart transplant program in New Jersey ranked by volume in the top 10 in the nation; the only lung transplant program in New Jersey; one of the country’s most comprehensive robotic surgery services, six nationally certified chest pain centers; accredited certified comprehensive and primary stroke centers, two kidney transplant centers which are in the top 10 of 240 programs in the country; a renowned neurology and neurosurgery program; highly respected assistive reproductive technology program; comprehensive cancer services for adults and children; nationally recognized geriatric services and renowned women’s and children’s services. Throughout Barnabas Health, our dedicated physicians, nurses and health professionals are committed to providing the highest quality of patient care and health education to the community and the region.